Five tumour associated antigens were found to be differentially expressed between the two subgroups from the TARGET database (standard versus low risk subgroup comparison) and between the three subgroups from the TCGA database (poor versus good, and intermediate versus good risk subgroup comparisons): SAGE1, MORC4, CEACAM3, SLC34A2 and STEAP1. This suggested an overlap in key processes that lead to AML and an impact on the clinical features that lead to the classification of patients into high/poor, standard/intermediate, or low/good risk subgroups. Here, SAGE1 is linked to acute myeloid leukemia.